Broken heart: depression in cardiovascular disease by Krishnan, K. Ranga R.
eart disease and depression are among the most
common diseases seen in developed countries.The rela-
tionship between heart disease and depression has been
the subject of both popular interest and scientific
research.Sadness is often portrayed as a feeling of heav-
iness in the chest or as a “broken heart.”Interestingly,as
we learn more about the expression of emotions, it
appears that these perceptions may simply be the lan-
guage representation of the somatic feelings.In this arti-
cle,I will review the scientific literature on the relation-
ship between heart disease and depression.(For a more
comprehensive discussion, the interested reader is
referred to an article by Jiang et al
1).There are three ques-
tions that I will address:first,whether depression is a risk
factor for heart disease;second,whether depression can
worsen the prognosis of heart disease; and third and
finally,the treatment of depression in the context of car-
diac disease.The cardiac disease that is the most common
and where the literature is the clearest is coronary artery
disease (CAD).The focus of this article will thus be pri-
marily on this condition.
How common is depression among 
cardiac patients?
Depression is not a surprising finding after an acute med-
ical event such as a heart attack.What is a surprise is that
the frequency is not higher.Cassem and Hackett
2 found
depressed mood to be common in 50% of patients imme-
diately following a myocardial infarction (MI).What is of
interest is that this is persistent, ie, more than 70% of
patients remain depressed a year after the event.Not only
was the depression present,but it also had functional con-
sequences such as being related to inability to return to
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Heart disease and depression are among the most com-
mon diseases seen in developed countries. The relation-
ship between heart disease and depression has been the
subject of both popular interest and scientific research.
Sadness is often portrayed as a feeling of heaviness in the
chest or as a “broken heart.” Interestingly, as we learn
more about the expression of emotions, it appears that
these perceptions may simply be the language represen-
tation of somatic feelings. Large, prospective, longitudi-
nal studies that have examined the relationship between
depression and development of coronary artery disease
(CAD) have shown that depression is a risk factor for the
development of CAD. Depression also increases mortality
in patients with stable CAD or myocardial infarction com-
pared with patients without depression. The recent
Sertraline AntiDepressant HeARt attack Trial (SADHART)
has shown that selective serotonin reuptake inhibitors like
sertraline can be safely used in patients with depression
following myocardial infarction. There is also intriguing
evidence that treating depression with antidepressants
may improve outcomes, including mortality.
Dialogues Clin Neurosci. 2003;5:167-174.work or previous activities, sexual difficulties, and re-
admission to hospital.This risk of developing depression
was highest among patients who had prior episodes of
depression.
3Those with a prior history of major depres-
sion account for 44% to 56%
4 of post-MI patients with
major depression.Dovenmuehle and Verwoerdt
5 found
that,among cardiac patients who experienced moderate-
to-severe depressive symptoms,what was interesting was
the absence of expected biological symptoms of depres-
sion. This is seen when more formal evaluations for
depression are conducted.
More formal psychiatric evaluations for diagnosing dis-
orders based on standardized criteria report lower rates.
Carney et al
6 examined 50 patients with documented
CAD (by coronary angiography);they found the preva-
lence of major depression to be only 18%. Similarly,
Schleifer et al
7 performed structured psychiatric inter-
views in 283 patients admitted for MI 8 to 10 days after
infarction and then again 3 to 4 months later. Initially,
nearly a fifth met criteria for major depression,but nearly
half the patients met diagnostic criteria for either minor
or major depression.The persistence of depression was
also documented:3 to 4 months later,a third of patients
continued to meet criteria for depression,including 75%
of those who had initially met criteria for major depres-
sion.To summarize,depressive symptoms are common,
but full-blown major depression is seen only in 20% of
patients.This depression is persistent.
What are the risk factors for the development
of depression among cardiac patients?
The risk factors that have been identified include nega-
tive life events unrelated to the cardiac condition and low-
ered subjective or perceived social support.
8Another pos-
sible risk factor is the development of silent ischemic
strokes in critical regions of the brain.
9 We and others
have shown that these strokes are common as people age,
and that,when these strokes occur in critical regions of
the brain such as the orbital frontal cortex (OFC),they
can lead to depression.
10The OFC is important in regu-
lating mood,and impairment in OFC function can lead to
persistent problems with negative reinforcement making
an individual vulnerable to depression.
11
Can depression early in life lead to cardiac dis-
ease or can you die from a broken heart?
This is an intriguing question.Table I summarizes results
of large studies that have attempted to address this ques-
tion.
12-20All these studies were longitudinal in nature.The
first study was a 12-year follow-up in a group of Swedish
women.
12The first US population study was reported in
1993,with a similar follow-up duration,but a much larger
sample that included both men and women.
14
An illustrative study is that of Ford et al,
19 who prospec-
tively followed all male medical students who entered
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Table I. Studies of the relationship between depression and prognosis of coronary artery disease (CAD), in people without preexisting CAD.
*Adjusted for multiple factors (varies between studies, in general age, conventional cardiovascular risk factors, such as smoking, choles-
terol, weight, or body mass index, and physical conditions at entry of the study). MI, myocardial infarction; RR, relative risk.
Study Age (years) Follow-up (years) RR*
Hallstrom et al
12 38-54 12 Severity of depression, predicted angina only
Appels and Mulder
13 39-65 4.5 RR=2.28 for nonfatal MI; no association with fatal MI
Anda et al
14 45-77 12.4 RR=1.5 for depressive affect
Aromaa et al
15 40-64 6.6 RR=3.36
Wassertheil-Smoller et al
16 ≥60 4.5 Deaths: RR=1.26
MI or stroke: RR=1.18
MI: RR=1.14, but not significant*
Barefoot and Schroll
17 50 24 Death: RR=1.59
MI: RR=1.71
Pratt et al
18 >18 13 MI: RR=4.54 for major depressive episode
MI: RR=2.07 for dysphoria
Ford et al
19 26±2 37 MI or CAD: RR=2.12
Mendes de Leon et al
20 65-99 9 Mortality: RR=1.03Johns Hopkins Medical School from 1948 to 1964. At
entry,the students completed a questionnaire about their
personal and family history and health status,and under-
went a routine medical examination.They were followed
yearly with a variety of questionnaires.The lifetime preva-
lence of clinical depression in this population was 12%.
Clinical depression was associated with an almost twofold
higher risk for later CAD.The usual risk factors,such as
smoking,alcohol use,body mass index,baseline choles-
terol level,hyperlipidemia,hypertension,and diabetes,
were all examined.The study also addressed the question
of whether there was a temporal relationship between
CAD and depression. Just showing an association
between depression and CAD is insufficient.The ques-
tion is how long after depression develops one can
demonstrate a risk for CAD. Ford suggested a broad
range from 1 year to 44 years.The one major limitation
was that the study was confined to men.
21
However,Hallstrom et al
12 had similar results in a study of
a community sample of women.Their study was conducted
in a wide age range of women between 38 and 54 years in
Gothenburg, Sweden.The women were followed for 12
years for the occurrence of angina pectoris,MI,and death.
Clinical depression was again associated a higher risk for
angina pectoris.The study did not show a clear relationship
between depression and other cardiovascular outcomes.
Of particular importance is the Epidemiologic Catchment
Study (ECA).This study was conducted by the National
Institute of Mental Health (NIMH) to assess the inci-
dence and prevalence of psychiatric disorders in the
USA.
18A structured psychiatric interview,the Diagnostic
Interview Schedule,was used for the clinical diagnosis of
major depression according to Diagnostic and Statistical
Manual of Mental Health Disorders,Third Edition (DSM-
III)
22 criteria.There were 5 sites in the initial study.One
of the sites in Baltimore followed up patients 13 years
later. Patients with major depression had a 4.5-times
higher risk of suffering a heart attack than did those with-
out major depressive disorder. Even depressed mood
alone increased the risk for MI.The finding that dyspho-
ria alone correlated with significantly increased relative
risks
13 for heart attack during a 13-year follow-up is
extremely interesting and brings up the question of
whether it is clinical depression that is important and
needed,or would just minor features of depression suf-
fice in increasing the risk for CAD.There are also nega-
tive studies that have shown no relation between depres-
sion and the development of CAD.
16,20,23,24 Some of these
showed effects in one gender, but not in the other. For
example, in the Established Populations for the
Epidemiological Studies of the Elderly (EPESE) pro-
ject,
20 there was an association between depressive symp-
toms and CAD in women,but not among men.The fact
that women develop CAD at an older age than men
might explain the results of this study. Also, the effect
seems to be less as people age,suggesting that this rela-
tionship may be more evident when depression is seen in
younger populations.
19
What we do know is that the preponderance of evidence
suggests that depression and possibly (modest levels of
evidence) just feeling sad may increase the risk for CAD.
Although the studies suggest that depression occurs
before the onset of clinically significant CAD,it is possi-
ble that atherosclerosis,which is the basis of CAD and is
known to begin at very young ages,may precede clinical
depression or may arise at the same time.
25Therefore,the
possibility that both diseases may have a common origin
remains open.
Why would depression increase 
the risk for CAD?
The most parsimonious explanation is that depression
reduces motivation and that individuals do not take care
of their general health,and this leads to the increased risk
for depression.In support of this,it is noted that depressed
patients exercise less,
26,27 eat poorly,do not take aspirin,
28-30
smoke more,and in general exhibit behaviors that increase
the risk for cardiac disease.A more interesting explana-
tion is that depression increases platelet aggregation.
Increased platelet aggregation,which plays a significant
role in coronary occlusion,is another recently uncovered
biological abnormality in depression.
31 Depressed ischemic
heart disease patients showed elevated β-thromboglobu-
lin levels,increased plasma levels of platelet factor 4,and
increased expression of the platelet surface receptors for
glycoprotein IIb/IIIa and P-selectin compared with non-
depressed subjects.
32 It is possible that these factors play a
mediating role on the effect of depression in the develop-
ment of CAD.
Can depression increase 
the chances of dying?
Dying from a broken heart is a common tale and one
that is accepted in the stories and literature of all cul-
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169tures.But what is the scientific evidence? Table II sum-
marizes the results of several studies investigating the
relationship of depression and mortality in patients with
recent MI (<2 months).
4,33-39These studies clearly docu-
ment that depression increases the risk of dying among
patients who have just had an MI.The relative risk ratio
attributable to depression differs among studies,but it is
clear that depression increases the risk of dying among
patients who have just had an MI.The relative risk ratio
for dying within 6 months among post-MI patients with
versus without major depressive disorder was reported
as 3.1 both by Schleifer in 1989
34 and by Frasure-Smith in
1993.
37 At 1 year, the relative risk ratio ranges remain
high.The long-term impact of major depression on mor-
tality after MI has not been as well studied. Frasure-
Smith et al
38 showed that the mortality rate of patients
with major depression remained elevated at 18 months,
but not after adjustment for cardiac risk variables.
Of particular interest is the finding that subclinical depres-
sion (Beck Depression Inventory [BDI] score ≥10)
increases mortality after MI.This raises the question of
whether the criterion-based diagnosis is the predictor or
whether just the symptoms were sufficient.It also raises the
question of whether there is a particular profile of symp-
toms necessary,or if just the will to live is the factor.Besides
mortality, the factor that is of interest is other cardiac
events.The data for cardiac events are sparse.Ladwig et al
40
noted that depressed post-MI patients had a threefold
higher rate of chest pain than nondepressed patients.This
could reflect angina or just increased awareness of pain,but
it probably contributes to increased costs due to the need
for increased assessment.
28,41-43 Few studies have evaluated
mortality following CAD rather than MI. Carney et al
44
noted the relative risk of a cardiac event was 2.2 times
higher in patients with major depression compared with no
depression.Barefoot and Schroll
17 from Duke University
in their study of 1250 patients who had undergone their
first angiogram noted that the Zung Depression Scale score
was significantly associated with increased risks for cardiac
mortality and all-cause mortality. Moderate-to-severe
depression increased the odds of cardiac death by nearly
70%. Even mild depression increased the odds by 38%
compared with nondepressed patients.The effect was most
pronounced in the first year and then decreased over the
next 4 years,and then remerged.
Can depression provoke ischemia?
A recent study evaluated the impact of depression on
ischemia using a laboratory model.Mental stress,which
can be provoked by a number of strategies,such as ask-
ing an individual to speak publicly,do mental arithmetic,
etc,has been shown to provoke ischemia that can be reli-
ably measured. Patients with established CAD and
depressive symptoms showed more ischemia during men-
tal stress testing.
45 Another way is to look for silent
ischemia during daily living.During the day when subjects
with CAD are evaluated using Holter monitoring to
record ischemic events,it is not uncommon to find evi-
dence of ischemia of which the patient is unaware. A
recent study used a rating scale to show that sadness and
feeling tense is associated with the silent ischemia.
46This
suggests that even emotions within the normal range can
play a role.
Why would depression lead to increased
chances of dying?
Patients with depression have been found to have elevated
plasma norepinephrine,increased heart rates,and reduced
heart-rate variability.
28,47-50 Reduced heart-rate variability
has been associated with increased mortality in both CAD
and chronic heart failure.
45,51 In fact,an association between
ventricular arrhythmia and depression has been noted.
Clearly,motivational problems due to depression proba-
bly play a role by reducing adherence to medical treat-
ment and possibly by increasing platelet aggregation.All
these factors could also play a role in increasing mortality.
The best evidence so far is that there is an interaction with
ventricular arrhythmia and depression.
37
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Table II. Studies of the relationship between depression and prognosis in
coronary artery disease (CAD), in people with preexisting CAD.
RR, adjusted relative risk ratio for mortality after myocardial infarc-
tion with versus without depression; OR, odds ratio.
Study n Follow-up RR*
(months)
Stern et al
4 68 12 7.5 (OR)
Schleifer et al
34 282 6 3.1
Ahern et al
35 265 12 -
Ladwig et al
36 552 6 4.9
2.8
Frasure-Smith et al
37 222 6 3.1
Frasure-Smith et al
38 218 18 6.64
Frasure-Smith et al
39 896 12 3.66
Kaufman et al
33 361 12 2.33Can we treat depression in heart disease 
and will it affect prognosis?
First,it is important to know that treatment studies are
very limited.Second,it is important to note that the treat-
ment of depression in this context remains limited.Only
10% to 25% of those with CAD and major depression
receive treatment.
34,52There are essentially three ways to
treat depression in cardiac patients:psychotherapy;med-
ication;and,in rare cases,electroconvulsive therapy.The
evidence for safety and efficacy for these treatments is
limited. Veith et al
53 in a small study of 24 depressed
patients with chronic heart disease showed that depres-
sion was significantly improved with either imipramine or
doxepin, but not placebo, after 4 weeks of treatment.
However,imipramine,doxepin,and other tricyclics may
not be the best option. Imipramine can, for example,
induce severe orthostatic hypotension, especially in
patients with impaired cardiac ventricular function.
54
These drugs also have quinidine-like cardiotoxic side
effects.This can be seen as QTc prolongation,conduction
delay, and block of the AV conjunction and bundle
branches,and can lead to atrial or ventricular arrhythmia,
ST-T abnormalities,and death.
55,56These factors were illus-
trated by a recent comparison of the selective serotonin
reuptake inhibitor (SSRI) paroxetine with nortripty-
line.
57,58 Both drugs were effective in treating depression.
However,25% of the patients on nortriptyline terminated
the study early because of adverse events,compared with
5% of those on paroxetine.Also,cardiac events were more
frequent among patients on nortriptyline (18%) compared
with paroxetine (2%).Moreover,other antidepressants,
such as tianeptine,are also known to be free of deleteri-
ous cardiovascular effects and interactions in polymed-
icated patients due to lack of action on cytochrome P-450;
tianeptine can thus be freely administered in depressed
patients with concomitant cardiovascular disease.
The data on newer drugs are very limited,as are the data
with regard to treatment of depression following MI.A
large,randomized trial has been recently completed,the
Sertraline AntiDepressant HeARt attack Trial (SAD-
HART),in which 369 patients from 40 sites were identi-
fied at hospitalization for an acute MI or unstable angina.
They were enrolled within 30 days of diagnosis of acute
coronary syndrome
59;64% were male;74% had MI.The
primary (safety) outcome measure was change from base-
line in left ventricular ejection fraction (LVEF);secondary
measures included surrogate cardiac measures and car-
diovascular adverse events.Patients were randomized to
sertraline or placebo.There was no minimum Hamilton
Depression (HAMD) score for entering the study.The
mean baseline HAMD score was 19.6±5.3.A prespecified
population was identified for evaluating the efficacy of ser-
traline.These were patients with a HAMD score >18 and
two previous episode of depression.The study lasted 24
weeks.On the Clincial Global Impression (CGI) scale,ser-
traline was more effective than placebo (P<0.05). The
CGI-Improvement responder rates for sertraline were sig-
nificantly higher than for placebo in the total sample (67%
vs 53%).For the efficacy evaluable population,the effect
of sertraline was more clear.
59 Sertraline had no significant
effect on mean LVEF,treatment-emergent increase in ven-
tricular premature complex (VPC) runs,QTc interval >450
ms at end point, or other cardiac measures. Mortality,
rehospitalization, and occurrence of peripheral edema
were all numerically lower in patients on sertraline com-
pared with those on placebo.The incidence of severe car-
diovascular adverse events was 14.5% with sertraline and
22.4% with placebo.The study was not powered to detect
a reduction in cardiac events.The results of the trial pro-
vide the first evidence that depression can be treated fol-
lowing an MI with an antidepressant. The ENhancing
Recovery In Coronary Heart Disease (ENRICHD)
study
60 examined the efficacy and safety of cognitive
behavioral therapy (CBT) in depression as well as patients
with low social support after MI.This study showed that
CBT was effective in treating depression following MI,but
did not reduce cardiac events.Another study provided
some support to the notion that treating depression may
improve cardiac outcomes.
61This was a case-control study
of depressed patients who were receiving antidepressants,
electroconvulsive therapy,or both.Both MI and all-cause
mortality were lower among patients who were ade-
quately treated for depression compared with the inade-
quately treated patients.
Several recent studies have assessed the effects of SSRIs
on platelet activity and heart-rate variability in depressed
patients,with or without heart disease.
Serebrauny et al,with other members of the SADHART
group including my own group,have recently shown that,
consistent with previous reports from the Columbia,
Pittsburgh,and Emory groups,platelet activation increased
in depression is reduced by sertraline.A significant advan-
tage for sertraline over placebo was seen for B throm-
boglobulin and P-selectin.
62
SSRIs appear to reduce the platelet aggregation in a vari-
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171ety of studies that have examined platelet function.
63-66 It
is possible that one of the mechanisms by which SSRIs
have a benefit is by their effect on platelet aggregation.
Conclusion
Depression is common among patients with heart disease.
It increases the risk of developing CAD.It also worsens
the prognosis of patients following MI or even in those
with CAD.The recent antidepressant study has clearly
shown that we can treat depression following an MI.The
overriding imperative should be to recognize depression
as early as possible and intervene appropriately.It is crit-
ical to continue to investigate whether the treatment of
depression can improve the poorer prognosis in patients
with CAD. ❏ 
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“Corazón roto”: depresión en la enfermedad
cardiovascular
La cardiopatía y la depresión están entre las enfer-
medades más frecuentemente observadas en paí-
ses desarrollados. La relación entre la cardiopatía y
la depresión ha sido motivo de interés tanto de la
población general como de la investigación cientí-
fica. La tristeza a menudo es representada como un
sentimiento de pesadez en el pecho o como un
“corazón roto.” Es interesante considerar que a
medida que se tiene un mayor conocimiento acerca
de la expresión de emociones, pareciera que estas
percepciones pudieran ser simplemente la repre-
sentación, mediante el lenguaje, de sentimientos
somáticos. Grandes estudios prospectivos y longi-
tudinales que han examinado la relación entre
depresión y desarrollo de enfermedad coronaria
(EC) han mostrado que la depresión constituye un
factor de riesgo para el desarrollo de EC. La depre-
sión también aumenta la mortalidad en pacientes
con EC estable o infarto al miocardio en compara-
ción con pacientes sin depresión. El reciente ensayo
SADHART (Sertraline AntiDepressant HeARt attack
Trial) ha mostrado que los inhibidores selectivos de
la recaptación de serotonina como la sertralina pue-
den utilizarse con gran seguridad en pacientes con
depresión post infarto al miocardio. También hay
interesantes constataciones que indican que el tra-
tamiento de la depresión con antidepresivos podría
mejorar su evolución incluyendo la mortalidad.
Cœur brisé : dépression dans la maladie 
cardio-vasculaire
La cardiopathie et la dépression font partie des
maladies les plus courantes des pays développés.
Les liens entre cardiopathie et dépression intéres-
sent tant le grand public que la recherche scienti-
fique. La tristesse est souvent représentée comme
un sentiment de pesanteur dans la poitrine ou
comme un « cœur brisé ». De façon intéressante,
notre meilleure connaissance de l’expression des
émotions suggère que ces perceptions puissent
être la représentation par le langage des sensa-
tions somatiques. De grandes études prospectives,
longitudinales qui ont étudié la relation entre
dépression et développement de la maladie coro-
naire (MC) ont montré que la dépression est un
facteur de risque pour le développement de la MC.
La dépression majore aussi la mortalité chez les
patients atteints de MC stable et chez les patients
atteints d’infarctus du myocarde comparés aux
patients non dépressifs. L’essai récent SADHART
(Sertraline AntiDepressant HeARt attack Trial) a
montré que les inhibiteurs sélectifs de la recapture
de la sérotonine comme la sertraline pouvaient
être utilisés en toute sécurité chez les patients
ayant eu une dépression après un infarctus du
myocarde. D’intéressantes constatations indiquent
que le traitement de la dépression par les antidé-
presseurs pourrait améliorer l’évolution, y compris
la mortalité.Depression in cardiovascular disease - Krishnan  Dialogues in Clinical Neuroscience - Vol 5 . No.2 . 2003
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